

Article 34

**Claims**

1. A method of preventing or controlling cataract or cataract-like disorders in the eye of a mammalian subject which comprises administering to the subject an effective amount of one or more inhibitors of TGF $\beta$ .
2. A method according to claim 1 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.
3. A method according to claim 2 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.
4. A method according to claim 2 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.
5. A method according to claim 2 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.
6. An ophthalmological formulation comprising one or more inhibitors of TGF $\beta$  in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.
7. An ophthalmological formulation according to claim 6 wherein the inhibitors of TGF $\beta$  are as defined in claim 2, 3, 4 or 5.
8. A method of preventing or controlling "aftercataract" formation in the eye of a mammalian subject following lens implant surgery which comprises implanting in the eye of the subject a lens coated with one or more TGF $\beta$  inhibitors.
9. A method according to claim 8 wherein the TGF $\beta$  inhibitors are as defined in claim 2, 3, 4 or 5.
10. A lens implant coated with one or more TGF $\beta$  inhibitors.
11. A lens implant according to claim 10 coated with one or more TGF $\beta$  inhibitors as defined in claim 2, 3, 4 or 5.
12. The use of inhibitors of TGF $\beta$  in the manufacture of an ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.

- 25 -

13. Use according to claim 12 wherein the TGF $\beta$  inhibitors are as defined in claim 2, 3, 4 or 5.

add  
A1

add  
B1

add  
C1

09643092 062196